MJ-26 is an inhibitor targeting Menin. MJ-26 has high binding affinity (Ki: 0.56 µM) and significant antiproliferative activity. MJ-26 works by inhibiting Menin-MLL interaction and inducing Menin protein degradation. MJ-26 has significant antitumor effects on acute myeloid leukemia (AML). MJ-26 can be used in AML research[1].
Molecular Weight:
757.97
Formula:
C38H47N9O4S2
Target:
Epigenetic Reader Domain
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
